The short version
A June 2025 Medsafe classification submission names Adamax and Semax as ACTH analogues marketed for cognitive enhancement. This identifies a regulatory discussion of the name, not a clinical demonstration of cognitive benefit.
An investigational profile is not an endorsement or a finding of safety.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Adamax
- Entry name · The name used for this encyclopedia topic.
No additional name variations have been documented for this entry yet. This is not a claim that none exist.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
What should be clarified before interpreting claims?
The cited submission is a historical proposal, not proof of current legal status, a verified molecular structure or a human efficacy result. Semax research cannot establish Adamax effects.
Identity and evidence scope · Medsafe · June 2025 peptide-classification submission ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
The cited submission is a historical proposal, not proof of current legal status, a verified molecular structure or a human efficacy result. Semax research cannot establish Adamax effects.
Research terms in everyday language ↗
This is a bounded context overview, not a completed clinical literature appraisal. The linked source has the scope stated here; related-compound findings are not evidence for this preparation.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- A name used for a marketed ACTH-related peptide analogue; exact structural claims need their own documentation.
- Name variations
- Names you may see and important distinctions
- Source type
- Historical regulatory proposal · name and class context
- Reference jurisdiction
- New Zealand · historical June 2025 submission; current status not assessed
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗